Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michaela Diamant

Showing results (11-20 of 212) with videos related to

Pageof 22
Sort By:
Diabetes Research and Clinical Practice|August 26, 2011
Glucolipotoxicity and beta cells in type 2 diabetes mellitus: target for durable therapy?Daniel H van Raalte, Michaela Diamant
Current Atherosclerosis Reports|January 10, 2013
Advances in pharmacologic therapies for type 2 diabetesLinde M Morsink, Mark M Smits, Michaela Diamant
Diabetes Care|August 30, 2007
Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patientsRoger K Schindhelm, Robert J Heine, Michaela Diamant
The American Journal of Psychiatry|October 7, 2004
Schizophrenia, syndrome X, and omega-3 fatty acidsFrançois Pouwer, Ritsaert Lieverse, Michaela Diamant, et al.
Current Diabetes Reports|June 6, 2007
Nonalcoholic fatty liver disease and cardiovascular disease riskRoger K Schindhelm, Michaela Diamant, Robert J Heine
Arteriosclerosis, Thrombosis, and Vascular Biology|December 17, 2010
Cell-derived microparticles in the pathogenesis of cardiovascular disease: friend or foe?Maarten E Tushuizen, Michaela Diamant, Augueste Sturk, et al.
Diabetes Research and Clinical Practice|February 2, 2010
Does glucagon-like peptide-1 receptor agonist therapy add value in the treatment of type 2 diabetes? Focus on exenatideRenate E van Genugten, Daniël H van Raalte, Michaela Diamant
Current Opinion in Clinical Nutrition and Metabolic Care|May 22, 2010
Pancreatic steatosis in humans: cause or marker of lipotoxicity?Daniël H van Raalte, Nynke J van der Zijl, Michaela Diamant
Diabetes Care|October 29, 2008
Association of 1,5-anhydroglucitol and 2-h postprandial blood glucose in type 2 diabetic patients: response to Stettler et alRoger K Schindhelm, Michaela Diamant, Henk J Bilo, et al.
Nature Reviews. Nephrology|December 31, 2013
The gut-renal axis: do incretin-based agents confer renoprotection in diabetes?Marcel H A Muskiet, Mark M Smits, Linde M Morsink, et al.
Pageof 22

Showing results (11-20 of 212) with videos related to

Sort By:
Pageof 22
Diabetes Research and Clinical Practice|August 26, 2011
Glucolipotoxicity and beta cells in type 2 diabetes mellitus: target for durable therapy?Daniel H van Raalte, Michaela Diamant
Current Atherosclerosis Reports|January 10, 2013
Advances in pharmacologic therapies for type 2 diabetesLinde M Morsink, Mark M Smits, Michaela Diamant
Diabetes Care|August 30, 2007
Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patientsRoger K Schindhelm, Robert J Heine, Michaela Diamant
The American Journal of Psychiatry|October 7, 2004
Schizophrenia, syndrome X, and omega-3 fatty acidsFrançois Pouwer, Ritsaert Lieverse, Michaela Diamant, et al.
Current Diabetes Reports|June 6, 2007
Nonalcoholic fatty liver disease and cardiovascular disease riskRoger K Schindhelm, Michaela Diamant, Robert J Heine
Arteriosclerosis, Thrombosis, and Vascular Biology|December 17, 2010
Cell-derived microparticles in the pathogenesis of cardiovascular disease: friend or foe?Maarten E Tushuizen, Michaela Diamant, Augueste Sturk, et al.
Diabetes Research and Clinical Practice|February 2, 2010
Does glucagon-like peptide-1 receptor agonist therapy add value in the treatment of type 2 diabetes? Focus on exenatideRenate E van Genugten, Daniël H van Raalte, Michaela Diamant
Current Opinion in Clinical Nutrition and Metabolic Care|May 22, 2010
Pancreatic steatosis in humans: cause or marker of lipotoxicity?Daniël H van Raalte, Nynke J van der Zijl, Michaela Diamant
Diabetes Care|October 29, 2008
Association of 1,5-anhydroglucitol and 2-h postprandial blood glucose in type 2 diabetic patients: response to Stettler et alRoger K Schindhelm, Michaela Diamant, Henk J Bilo, et al.
Nature Reviews. Nephrology|December 31, 2013
The gut-renal axis: do incretin-based agents confer renoprotection in diabetes?Marcel H A Muskiet, Mark M Smits, Linde M Morsink, et al.
Pageof 22